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Abstract
Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B
(CHB) patients in Turkey and to study related factors.
Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers.
Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving
antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers.
Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and
Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant.
Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five
hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %)
and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found
that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied
according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL
was determined in inactive HBV patients when matched controls with the associated factors were provided.
Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease
becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.
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Background
There are approximately 250 million individuals with
chronic hepatitis B (CHB) around the world [1]. Turkey
is ranked as a lower intermediate-endemic country with
a prevalence of hepatitis B virus (HBV) that varies be-
tween 3 and 10 % in different regions [1, 2]. As the
prevalence of CHB increase, prevention by education
and vaccination in those uninfected and maintaining a
“good quality of life” in those infected is crucial.
Quality of life means the general perception of positive
and negative aspects of an individual [3]. Health is a very
substantial part of the general quality of life. The con-
cept of health related quality of life (HRQOL) and its
markers began to emerge in the 1980s. In the last few
decades, in parallel to the recognized significance of the
quality of life of patients, there has been an increase in
the assessment of HRQOL among patients with chronic
liver disease. Particularly in some countries, monitoring
HRQOL in chronic hepatitis C patients has become a
standard procedure [4]. Similarly, the awareness of the
importance of HRQOL assessment in CHB has increased
[5–12]. Unfortunately, based on the results obtained from
a healthy population, some results point to a decrease in
quality of life in CHB patients [5]. HRQOL may worsen
due to the progression of viral hepatitis [7].
For many years, CHB patients were assessed for HRQOL
using generic scales that were developed to measure the
quality of life in the general population [5–11]. The devel-
opment of the Hepatitis B Quality of Life Instrument
(HBQOL) by Spiegel et al. [13] filled an important gap
regarding the assessment of CHB patients, using a spe-
cial scale for the disease. After this development, a
small number of studies carried out with the HBQOL
were reported in the literature [14, 15]. The quality of
life in Turkey was found to be quite low in various
studies where different scales were used in CHB pa-
tients [5, 11]. Unfortunately, there have been no studies
of the Turkish population that assessed quality of life in
CHB patients using the HBQOL and in a nationwide
extent. Therefore, we planned to assess HRQOL of a
wide and heterogeneous group of CHB patients using
the HBQOL scale and considering different properties.
Methods
Study design
This multi-center study was carried out prospectively
between January 1 and April 15 2015, in 30 provinces
in Turkey. A total of 57 centers comprised from 23
university hospitals, 21 training hospitals and 13 state
hospitals participated in this study. Participating hospi-
tals were widely scattered throughout the country, as
presented in Fig. 1.
All CHB patients attending infectious disease out-
patient clinics of participating hospitals over the study
period were evaluated with a standardized interview.
The study population included all who were eligible for
participation, aged 18 years or over, and who provided
informed consent. Accordingly, inactive carriers of
Fig. 1 The cities where the participant centers in this study are located in Turkey. * The signs indicate the number of centers
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HBsAg, chronic hepatitis B-infected patients, pre-cirrhotic
cases (patients with fibrosis score five and without cir-
rhotic symptoms) and those being treated for chronic
HBV infection were included in the study and were di-
vided into the following three groups below:
a) Group 1: HBsAg positive, HBeAg negative, with
normal alanine aminotransferase level (ALT) levels,
patients with a HBV Deoxyribonucleic acid (DNA)
level < 2000 IU/ml and who were not receiving
therapy.
b) Group 2: Chronic hepatitis B patients from any of
the groups receiving antiviral therapy.
c) Group 3: Chronic hepatitis B patients who were not
receiving antiviral therapy yet and who were not
inactive HBsAg carriers.
ALT levels in our study were interpreted according
to reference values used in the labs of each participat-
ing center.
The exclusion criteria were as follows: 1. Hepatitis C
virus (HCV) infection, 2. Any type of cirrhosis, 3. Liver
failure, 4. Liver cancer, 5. Presence of other liver
disorders.
Data collection tools
Data were collected using a standardized questionnaire
(SQ) via a face-to-face interview, a Turkish version of
Short Form-36 (SF-36) and a Turkish version of
HBQOL. The study questionnaire included a total of
16 questions on sociodemographic characteristics and
chronic HBV-related issues [14].
Hepatitis B Quality of Life Instrument version 1.0-HBQOL
We used the hepatitis B quality of life instrument ques-
tionnaire produced by Spiegel in 2007 [13]. This ques-
tionnaire was subsequently verified by Pinar et al. [14]
in a Turkish population. The subscales are listed as Psy-
chological Well-Being, Anticipation Anxiety, Vitality,
Stigma, Transmissibility and Vulnerability. There are 31
expressions having Likert type scoring from 1 to 5. The
higher the scores in the subscales and in the total scale
were interpreted as a better quality of life [13, 14].
The scale has undergone reliability and validity ana-
lyses, however, the Transmissibility subscale was found
not to be reliable or valid in a Turkish population. It was
assumed that after this subscale was removed the scale
would become available and compatible for Turkish
CHB patients [14].
At initiation of this study, researchers investigated the
internal consistency of HBQOL subscales in the study
population and showed high scores for each subscale.
Cronbach’s alpha values were above 0.77 for subscales of
Psychological Well-Being (0.93), Anticipation Anxiety
(0.93), Vitality (0.84), Stigma (0.89) and Vulnerability
(0.77) but were below acceptability (0.45) for Transmis-
sibility subscales, confirming Pinar et al.’s earlier work
[14]. Accordingly, transmissibility scores were not con-
sidered in calculation of the total score in this study,
where total possible scores within the range of 28–152
were transferred to corresponding scores out of 100.
Medical outcomes scale 36 item short form health
survey-SF 36
This scale was developed by Ware and Sherburne in
1989 and was adapted into Turkish by Pinar et al. [16]
and Kocyigit et al. [17]. The scale consists of 36 expres-
sions. It contains two main headings, recognized as the
Physical Component Summary and the Mental Compo-
nent Summary. General Health, Vitality, Physical Func-
tioning, Role Physical, Bodily Pain, Mental Health, Role
Emotional and Social Functioning compose the sub-
scales of the scale. Median scoring for each subscale is
calculated by the Likert method, according to a standard
SF-36 scoring algorithm [18]. Higher scores demonstrate
better functionality or a much better life quality [16].
This survey was reprinted with permission from the
RAND Corporation [18].
Ethics
Declaration of Helsinki and Good Clinical Practice
Guidelines were respected during the entire process of
enrolling patients in the study and collecting/analyzing/
reporting data. An approval from the local ethics com-
mittee was obtained for the study. Volunteering was
the main option for participating in the study.
Statistical analysis
All statistical analyses were conducted using the SPSS
v.22.0 statistical software package (SPSS Inc., Chicago,
IL, USA). Distributions of categorical variables were
tested using Chi-square test. Mann-Whitney U and
Kruskal-Wallis Tests were used for comparison of
groups; Bonferroni corrections were calculated for bin-
ary comparisons. Normality assumption was tested for
all continuous variables using Kolmogorov-Smirnov test:
median, 25th and 75th percentile values are presented
for continuous variables, if the normality assumption
was not valid. Spearman Correlation Test was used for
correlation between continuous variables.
Quality of life among patients with chronic HBV infec-
tion was further modeled using Covariance Analysis,
where the total score from the HBQOL scale and activity
of the disease were considered as the main dependent
and independent variables, respectively, while gender,
marital status, comorbidity, presence of HBeAg, serum
ALT, current treatment status and type of hospital were
treated as potential confounders. Statistical significance
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was set at p < 0.05, if not stated otherwise. Type I error
was set at 0.0167 for bivariate comparisons where three
or more groups were compared simultaneously.
Results
Sociodemographic characteristics of patients
Sociodemographic characteristics of patients and proper-
ties related to the disease are presented in Table 1. Sig-
nificant differences were determined for all properties
among patient groups (p < 0.05 for all).
SF-36 results
SF-36 results according to patient properties
All studied factors were found to be statistically signifi-
cantly associated with Mental Component summary
scores (p <0.05 for all). Similarly, all factors with the ex-
ception of marital status (p = 0.725) and HBeAg status
(p = 0.082) were significantly associated with the Phys-
ical Component Summary score. Differences according
to sociodemographic properties of patients with a sub-
scale of the SF-36 scale are summarized in Table 2.
A negative correlation was observed between the
subscale scores of patient age and Physical Functioning
and a positive correlation between the subscale scores
of patient age and Role Emotional, Mental Health and
Social Functioning. We also observed that the ALT
level did not affect the subscale of Vitality, but ele-
vated ALT did decrease the scores in the other sub-
scales. It was also determined that Vitality, Physical
Component Summary and Mental Component Sum-
mary scores were not affected by the HBV DNA level,
but negatively affected the scores in other subscales.
We found that the duration of diagnosis of the disease
and the period of therapy did not affect SF-36 scores
at all (Table 3).
SF-36 results according to patient groups
We found that Group 1 patients had the highest scores
among the patient groups. We determined that there
was no difference between Group 1 and Group 2 patients
for subscales of Vitality and Bodily Pain (respectively, p =
0.060, p = 0.185) while a significant difference was found
in other subscales. However, scores were similar only in
Vitality subscales between Group 1 and Group 3 patients
(p = 0.167), while a significant difference was found in
others. There was a significant difference between Group
2 and Group 3 patients for subscales of Bodily Pain,
Mental Health and Social Functioning (respectively,
p = 0.013, p = 0.016, p = 0.006), while results were similar
for other subscales (Table 4).







p value* All patients
(n = 4257)
Gendera Male 805 (52,6) 1095 (63,6) 659 (65,4) <0,001 2559 (60,1)
Age (years) b 42 (32;52) 42 (32;52) 34 (25; 44) <0,001 40 (30;50)
Marriage statusa Married 1256 (82,1) 1359 (79) 664 (65,9) <0,001 3279 (77)
Education levela Elementary school graduate
and under
654 (42,8) 672 (39) 359 (35,7) 0,002 1685 (39,6)
Middle school graduate 239 (15,6) 314 (18,2) 186 (18,5) 739 (17,4)
High school graduate 366 (23,9) 376 (21,8) 250 (24,8) 992 (23,3)
University graduate or higher 270 (17,7) 359 (20,9) 212 (21,1) 841 (19,8)
Regular incomea Present 893 (58,4) 1149 (66,8) 568 (56,4) <0,001 2610 (61,3)
Any family member(s) with
hepatitis Ba
Present 740 (48,4) 983 (57,1) 606 (60,2) <0,001 2329 (54,7)
Other chronic diseasea Present 373 (24,4) 484 (28,1) 196 (19,5) <0,001 1053 (24,7)
Hospital typea Training hospital 725 (47,4) 752 (43,7) 425 (42,2) <0,001 1902 (44,7)
University hospital 491 (32,1) 655 (38,1) 291 (28,9) 1437 (33,8)
Other 313 (20,5) 314 (18,2) 291 (28,9) 918 (21,6)
Duration of diagnosis (months)b 84 (36;144) 84 (48;156) 72 (24;132) <0,001 84 (36;144)
Period of therapy (months)b N/A 36 (1–312, 12;60) N/A 36 (1–312, 12;60)
ALT (U/L)b 21 (16;27) 26 (19;36) 34 (22;61) <0,001 25 (18;36)
HBV DNA (IU/ml)b 80 (0;462,5) 0 (0;117) 7600 (2001;13 × 104) <0,001 76 (0;1700)
HBeAg statusa Positive 0 358 (20,8) 242 (24) 0,049 600 (14,1)
*p-value for comparison of distribution across three disease groups. Other chronic disease: respectively; hypertension, diabetes mellitus, psychiatric disorders,
malignancy, chronic renal failure, congestive heart failure and others
aNumber (percent), bMedian (% 25; % 75); ALT alanine aminotransferase, HBV Hepatitis B Virus, DNA Deoxyribonucleic acid
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Gender p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001
Male 90 (70;100) 100 (50;100) 100 (33,3;100) 55 (45;75) 72 (56;84) 87,5 (62,5;100) 100 (77,5;100) 65 (50;75) 79 (61,5;86) 74 (54,9;82,3)
Female 80 (55;100) 100 (25;100) 100 (0;100) 50 (35;65) 64 (48;80) 87,5 (50;100) 80 (55;100) 60 (40;70) 68,5 (47;84) 64,1 (44,6;80,8)
Marriage status p:0,376 p:0,069 p:0,005 p:0,292 p:<0,001 p:<0,001 p:0,378 p:0,073 p:0,725 p:0,009
Married 90 (65;100) 100 (50;100) 100 (33,3;100) 50 (40;70) 68 (52;84) 87,5 (62,5;100) 90 (67,5;100) 65 (45;75) 76 (55,5;84) 71 (51,5;80,8)
Single 90 (65;100) 100 (43,7;100) 100 (33,3;100) 55 (40;75) 66 (48;80) 87,5 (50;100) 90 (67,5;100) 60 (40;75) 75 (54,5;86) 67,9 (46,9;81,2)
Education level p:<0,001 p:<0,001 p:0,011 p:<0,001 p:<0,001 p:0,013 p:<0,001 p:<0,001 p:<0,001 p:<0,001
Elementery school and under 85 (55;100) 100 (25;100) 100 (33,3;100) 50 (40;65) 68 (52;84) 87,5 (62,5;100) 90 (65;100) 60 (45;70) 71,5 (52;84) 68,5 (48,8;80,8)
Middle school 85 (60;100) 100 (25;100) 100 (33,3;100) 55 (40;70) 68 (52;80) 75 (62,5;100) 90 (67,5;100) 60 (40;70) 72 (52;84) 68,4 (48,8;80,8)
High school 90 (70;100) 100 (50;100) 100 (33,3;100) 55 (40;75) 68 (52;80) 87,5 (62,5;100) 100 (67,5;100) 60 (45;75) 78 (56;86) 72,3 (50,5;81,9)
University 95 (80;100) 100 (75;100) 100 (33,3;100) 60 (45;75) 72 (56;84) 87,5 (62,5;100) 100 (77,5;100) 65 (50;75) 80 (66;87) 74,6 (56,6;83,3)
Regular income p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001
Yes 95 (70;100) 100 (50;100) 100 (66,7;100) 55 (45;75) 72 (56;84) 87,5 (62,5;100) 100 (77,5;100) 65 (50;75) 80 (62;86) 74,8 (56,8;82)
No 80 (50;95) 75 (25;100) 66,7 (0;100) 50 (35;65) 64 (48;80) 75 (50;100) 77,5 (55;100) 55 (40;70) 67,5 (45;83) 62 (43,1;78,6)
Family members with hepatitis B p:0,003 p:0,003 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001
Present 85 (60;100) 100 (25;100) 100 (33,3;100) 50 (40;70) 68 (52;80) 87,5 (62,5;100) 90 (67,5;100) 60 (45,70) 73,5 (53,5;84) 68,3 (48,6;80,8)
Not 90 (70;100) 100 (50;100) 100 (33,3;100) 55 (40;70) 70 (52;84) 87,5 (62,5;100) 100 (67,5;100) 65 (45;75) 78 (57;86) 72,6 (52,8;82,1)
Received treatment for hepatitis B p:<0,001 p:0,001 p:0,016 p:0,164 p:0,481 p:0,763 p:0,712 p:0,006 p:<0,001 p:0,012
Yes 85 (60;100) 100 (25;100) 100 (33,3;100) 55 (40;70) 68 (52;80) 87,5 (62,5;100) 90 (67,5;100) 60 (45;70) 74 (54,5;84) 69,4 (50;80,8)
No 90 (65;100) 100 (50;100) 100 (33,3;100) 50 (40;70) 68 (52;84) 87,5 (62,5;100) 90 (67,5;100) 65 (45;75) 77 56,5;85,8) 71,5 (50,5;81,4)
Other chronic disease p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001
Present 75 (50;95) 75 (0;100) 66,7 (0;100) 50 (35;60) 64 (48;80) 75 (50;100) 77,5 (55;100) 55 (35;70) 64,5 (43;82) 63,3 (41,2;79,2)
Not 90 (70;100) 100 (50;100) 100 (33,3;100) 55 (45;75) 68 (52;84) 87,5 (62,5;100) 100 (77,5;100) 65 (50;75) 78 (60;86) 72,8 (53,6;82)
Hospital p:<0,001 p:<0,001 p:<0,001 p:0,291 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001
Training hospital 95 (73,7;100) 100 (75;100) 100 (66,7;100) 50 (45;70) 72 (56;84) 100 (62,5;100) 100 (77,5;100) 65 (50;75) 80,5 (62,5;85) 75,7 (57,6;81,2)
University hospital 85 (60;100) 100 (25;100) 100 (33,3;100) 55 (40;70) 64 (52;80) 87,5 (62,5;100) 90 (67,5;100) 60 (45;75) 73 (52,7;84) 67,6 (48,8;80)
Other 80 (55;100) 75 (25;100) 66,7 (0;100) 55 (35;70) 64 (48;80) 75 (50;100) 77,5 (55;100) 60 (40;70) 67 (47,4;83) 61,2 (43,1;80)
HBeAg status p:0,877 p:0,079 p:0,034 p:0,135 p:0,357 p:0,014 p:0,466 p:0,014 p:0,082 p:0,010
Positive 90 (65;100) 100 (25;100) 100 (33,3;100) 50 (40;70) 68 (52;80) 87,5 (50;100) 90 (67,5;100) 60 (45;70) 74 (54,5;84) 68,6 (48,7;80,8)
Negative 90 (65;100) 100 (50;100) 100 (33,3;100) 55 (40;70) 68 (52;84) 87,5 (62,5;100) 90 (67,5;100) 60 (45;75) 76 (55,5;85) 70,8 (50,8; 81)


















Table 3 Correlation of Short Form-36 and Hepatitis B Quality of Life scores with selected patient and disease characteristics (r/p)a
Subscale Age (years) Duration of diagnosis (months) Period of therapy (months) ALT (U(L) HBV DNA (IU(ml)
SF-36
Physical functioning −0,087/<0,001 0,009/0,553 −0,019/0,210 −0,037/0,015 −0,038/0,014
Role physical, −0,018/0,235 0,002/0,906 0,013/0,382 −0,045/0,003 −0,035/0,024
Role emotional 0,052/0,001 0,002/0,895 0,016/0,303 −0,042/0,006 −0,043/0,005
Vitality 0,01/0,521 −0,034/0,025 0,013/0,399 −0,020/0,187 −0,028/0,068
Mental health 0,107/<0,001 0,004/0,781 0,024/0,123 −0,042/0,006 −0,051/0,001
Social functioning 0,062/<0,001 −0,019/0,216 0,027/0,076 −0,076/<0,001 −0,042/0,006
Bodily pain −0,008/0,580 −0,003/0,844 0,035/0,023 −0,068/<0,001 −0,055/<0,001
General health 0,029/0,061 0,002/0,873 0,012/0,421 −0,044/0,004 −0,052/0,001
Physical component score 0,013/0,401 0,009/0,557 0,013/0,384 −0,044/0,004 −0,022/0,153
Mental component score 0,013/0,393 0,004/0,802 0,023/0,136 −0,032/0,038 −0,021/0,181
HBQOL
Psychological Well-Being 0,010/0,526 0,004/0,771 0,020/0,195 −0,051/0,001 −0,012/0,421
Anticipation anxiety 0,106/<0,001 −0,003/0,827 −0,011/0,471 −0,043/0,005 −0,049/0,001
Vitality 0,063/<0,001 0,009/0,578 −0,010/0,514 −0,045/0,003 0,608/<0,001
Stigma 0,124/<0,001 0,050/0,001 0,003/0,843 −0,049/0,001 −0,052/0,001
Vulnerability 0,091/<0,001 0,004/0,789 −0,011/0,488 −0,048/0,002 −0,046/0,003
Total score 0,009/0,568 0,003/0,870 0,015/0,343 −0,049/0,001 −0,024/0,125
aCorrelation coefficient (r) and relevant p value (in paranteses) are presented, ALT alanine aminotransferase level, SF-36 Short Form-36, HBQOL Hepatitis B Quality
of Life, HBV Hepatitis B Virus, DNA Deoxyribonucleic acid
Table 4 Distribution of Short Form-36 and Hepatitis B Quality of Life subscale scores of patients with hepatitis B by disease status
at study entry
Group-1 (n = 1529) Group-2 (n = 1721) Group-3 (n = 1007) p value All patients (n = 4257)
SF-36
Physical functioning 90 (70;100) 85 (60;100) 90 (65;100) <0,001┼, ╪,0,203§ 90 (65;100)
Role physical, 100 (50;100) 100 (25;100) 100 (25;100) <0,001┼, ╪,0,721§ 100 (50;100)
Role emotional 100 (33,3;100) 100 (33,3;100) 100 (33,3;100) 0,001┼,0,004╪, 0,859§ 100 (33,3;100)
Vitality 50 (45;70) 55 (45;70) 55 (40;70) 0,060┼,0,167╪,0,819§ 55 (40;70)
Mental health 72 (52;84) 68 (52;80) 68 (52;80) 0,005┼,<0,001╪, 0,016§ 68 (52;84)
Social functioning 87,5 (62,5;100) 87,5 (62,5;100) 87,5 (50;100) 0,012┼,<0,001╪,0,006§ 87,5 (62,5;100)
Bodily pain 100 (67,5;100) 90 (67,5;100) 90 (65;100) 0,185┼, <0,001╪,0,013§ 90 (67,5;100)
General health 65 (45;75) 60 (45;70) 60 (45;75) <0,001┼, ╪,0,775§ 60 (45;75)
Physical component score 79 (58,5;86) 74 (54,5;84) 74 (54;85) <0,001┼, ╪,0,644§ 75,5 (55,5;85)
Mental component score 74 (52,4;81,8) 69,4 (50;80) 67,8 (49;80,8) <0,001┼,╪,0,511§ 70,6 (50,3;80,8)
HBQOL
Psychological Well-Being 90 (67,5;97,5) 85 (70;95) 82,5 (65;95) 0,019┼,<0,001╪,0,090§ 85 (67,5;95)
Anticipation anxiety 80 (56,7;93,3) 76,6 (53,3;90) 70 (50;90) 0,008┼, <0,001╪, 0,001§ 76,6 (53,3;93,3)
Vitality 80 (64;88) 76 (64;88) 76 (60;88) <0,001┼,0,001╪,0,758§ 80 (64;88)
Stigma 93,3 (73,3;100) 90 (73,3;100) 90 (70;100) 0,056┼, 0,001╪,0,071§ 90 (73,3;100)
Vulnerability 80 (60;93,3) 80 (60;93,3) 73,3 (53,3;93,3) <0,001┼,╪,0,300§ 80 (60;93,3)
Total score 85 (67,1;93,6) 80,7 (66,4;91,4) 79,3 (63,9;90,7) <0,001┼,╪,0,024§ 81,4 (65,7;92,1)
SF-36 Short Form-36, HBQOL Hepatitis B Quality of Life, Median (25 %, 75 %) are presented, Bonferroni correction was used, ┼significant difference was obtained
in comparing group 1 and 2, ╪significant difference was observed between group 1 and 3, §significant difference was observed between group 2 and 3, bold data
reflected a statistical significance
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HBQOL results
HBQOL results according to patient properties
The relationship of the obtained HBQOL scores with
potential markers was studied. In male and married
patients who did not receive CHB therapy, and without
another chronic disease present and who were
followed-up at a training hospital and were found to be
HBeAg negative, it was observed that the total score
was significantly higher when compared to other
groups (p < 0.05 for all). Variances determined in the
distribution of scores according to the properties of
patients regarding their HBQOL subscales are pre-
sented in Table 5. We determined that age did not have
an effect on Psychological Well-Being, or total scores,
while scores in other subscales demonstrated an increase
associated with age. We also observed that the period of
therapy had no effect on the total score and all the sub-
scale scores. Only the subscale scores of Stigma were in-
creased in case of longer periods after the diagnosis of the
disease, while other subscales were not affected. It was
also determined that there is a reverse correlation between
elevated ALT levels and all subscale scores and in the total
score of the HBQOL scale. A relationship between HBV
DNA level and Psychological Well-Being and total score
was not found; however, a positive correlation was found
between HBV DNA levels and Vitality subscale while
there was a negative correlation between HBV DNA levels
and other subscales (Table 3).
Table 5 Distribution of Hepatitis B Quality of Life subscale scores by some socio-demographic and disease-related characteristics
of patientsa
Variable Psychological Well-Being Anticipation anxiety Vitality Stigma Vulnerability Total score
Gender p:<0,001 p:<0,001 p:<0,001 p:0,921 p:0,003 p:0,001
Male 87,5 (70;97,5) 76,7 (56,7;93,3) 80 (64;92) 90 (73,3;100) 80 (60;93,3) 82,8 (67,1;92,8)
Female 85 (65;95) 73,3 (50;93,3) 76 (60;88) 90 (73,3; 100) 80 (60;93,3) 80 (63,6;91,4)
Marriage status p:0,001 p:<0,001 p:0,341 p:<0,001 p:<0,001 p:0,002
Married 87,5 (70;95) 76,7 (56,7;93,3) 80 (64;88) 90 (73,3;100) 80 (60;93,3) 82,1 (67,1;92,8)
Single 82,5 (65;95) 73,3 (50;90) 76 (60;92) 86,7 (66,7;100) 73,3 (53,3;93,3) 78,6 (62,8;90,7)
Education level p:0,441 p:0,121 p:<0,001 p:0,001 p:0,089 p:0,881
Elementery school and under 87,5 (67,5;95) 76,7 (53,3;93,3) 76 (60;88) 93,3 (73,3;100) 80 (60;93,3) 81,4 (65,7;93,6)
Middle school 82,5 (68;95) 73,3 (50;90) 76 (64;88) 86,7 (66,7;100) 80 (53,3;93,3) 80,7 (62,8;91,4)
High school 87,5 (70;95) 76,7 (54,2;90) 80 (64;92) 90 (73,3;100) 80 (60;93,3) 82,1 (67,8;92,8)
University 85 (70;97,5) 76,7 (56,6;90) 80 (68;92) 90 (73,3;100) 80 (60;93,3) 82,1 (67,1;91,4)
Regular income p:0,005 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:0,077
Yes 90 (72,5;97,5) 80 (60;93,3) 80 (64;92) 93,3 (76,7;100) 80 (60;93,3) 84,3 (70;93,6)
No 80 (62,5;95) 70 (46,7;86,7) 72 (56; 88) 86,7 (66,7;100) 73,3 (53,3;93,3) 77,1 (60,7;89,3)
Family members with hepatitis B p:0,328 p:0,015 p:<0,001 p:0,082 p:0,002 p:0,097
Present 85 (67,5;95) 73,3 (53,3;90) 76 (60;88) 90 (73,3;100) 80 (60;93,3) 80,7 (65;91,4)
Not 87,5 (67,5;97,5) 76,7 (54,2;93,3) 80 (64;92) 90 (73,3;100) 80 (60;93,3) 82,9 (67,1;92,8)
Received treatment for hepatitis B p:0,001 p:0,070 p:0,179 p:0,066 p:0,917 p:0,011
Yes 85 (70;95) 76,7 (53,3;90) 76 (64;88) 90 (73,3;100) 80 (60;93,3) 80,7 (66,4;91,4)
No 87,5 (67,5;95) 76,7 (53,3;93,3) 80 (64;88) 90 (73,3;100) 80 (60; 93,3) 82,1 (65;92,8)
Other chronic disease p:0,003 p:0,385 p:<0,001 p:0,988 p:0,010 p:<0,001
Present 85 (65;95) 76,7 (53,3;93,3) 72 (56;88) 90 (73,3;100) 80 (53,3;93,3) 79,3 (63,6;91,4)
Not 87,5 (70;95) 76,7 (53,3;93,3) 80 (64;92) 90 (73,3;100) 80 (60;93,3) 82 (66,4;92,1)
Hospital type p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001 p:<0,001
Training hospital 90 (72,5;95) 80 (60;93,3) 84 (68;88) 93,3 (76,7;100) 80 (66,7;93,3) 85,7 (70,7;93,6)
University hospital 85 (65;97,5) 73,3 (50;86,7) 76 (60;88) 90 (70;100) 73,3 (53,3;93,3) 80 (63,6;90)
Other 80 (62,5;95) 70 (46,7;86,7) 72 (56;88) 86,7 (63,3;100) 73,3 (53,3;86,7) 76,4 (59,3;88,6)
HBeAg status p:<0,001 p:0,098 p:0,015 p:0,022 p:<0,001 p:<0,001
Positive 82,5 (65;95) 73,3 (50;90) 76 (60;88) 86,7 (66,7;100) 73,3 (53,3;93,3) 79,3 (62,9;91,4)
Negative 87,5 (67,5;95) 76,7 (53,3;93,3) 80 (64;88) 90 (73,3;100) 80 (60;93,3) 82,1 (66,4;92,1)
aValues were not normally distributed; thus; median (% 25; % 75) scores are presented in cells, bold data reflected a statistical significance
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HBQOL results according to patient groups
The total score and all the subscale scores of this scale
had higher levels in Group 1 patients. Excluding the
Stigma subscale (p = 0.056) between Group 1 and Group
2 patients, a significant difference was observed for sub-
scales and total scores. However, a significant difference
was found in all subscales and total scores between
Group 1 and Group 3 patients (p < 0.05 for all). There
was a significant difference in the Anticipation Anxiety
subscale (p < 0.001) and total scores (p = 0.024) between
Group 2 and Group 3 patients, while scores determined
in other subscales were similar (Table 4).
In multivariate analysis (Table 6), HBQOL total score
was statistically significantly associated with activity of the
disease, controlling for gender, marital status, presence of
at least one other chronic disease, current treatment status
and serum ALT level.
Discussion
HRQOL of CHB patients may vary according to their
socio-demographic properties. In studies conducted using
different scales, it was determined that educational level
[6], age [10], education period [11], annual income level
[10], duration of the disease and receipt of antiviral ther-
apy [10] affected HRQOL. In this study, HRQOL scores
were found to be significantly lower in women, singles,
and patients with other chronic diseases. Regarding other
important non-hepatitis health issues, quality of life had
been reported to be reduced in women [19–21], singles
[22] and patients with another chronic disorder [19, 23]. It
is well known that women, in many parts of the world,
receive less social support when compared to men when
they experience chronic disorders. Additionally, their
access to medical care is generally delayed compared with
men and they are either obliged to work or take over their
responsibilities before they get completely well [24]. These
variations between genders may cause quality of life to be
worse in female patients with CHB. Apart from these,
being married may provide social, psychological and
economic support and may improve the opportunity to
live healthier [25, 26]. Therefore, singles may have a
difficult time overcoming long-term disease and their
quality of life may rapidly deteriorate. In some cases,
comorbidities may reduce HRQOL more than the
primary disorder [27]. Furthermore, the frequency of a
referral to a hospital increases with more comorbidity
[28]. The quality of life can deteriorate in CHB patients
due to an increase in physical limitations because of
another disorder leading to a decrease in the ability to
become self-sufficient, utilization of multiple therapies
or receiving more medical care.
Based on our data, we found that the quality of life of
patients might decrease due to activation of the disease
when factors that have an effect on HRQOL are further
analyzed. Serum ALT level usually appears to be higher
in active CHB patients [29]. HRQOL had significant
relationship with ALT levels in our study. Accordingly,
we think that active patients could have psychiatric
consequences of the disease. Because these patients are
frequently called back for control visits to check the
activity of the disease, this may somehow lead to an
increase in anxiety among these patients.
In our study, one can easily notice the presence of
body pain experienced by patients who were receiving
therapy during the active term of the disease. On the
other hand, this group also had a better status of men-
tal and social functionality and a decrease in anxiety.
Additionally, the total scores obtained from the HBQOL
questionnaire have demonstrated that patients with active
disease undergoing therapy had increased quality of life.
The main purpose and scope of current therapies is to
avoid the formation of complications due to CHB [29].
However, these results reveal that antiviral therapies pro-
vided confidence to patients and increased their quality of
life. This result can be assumed as an additional success of
antiviral therapy.
According to the results we obtained from the SF-36
scale, not all of the CHB patients enrolled in our study
felt themselves to be energetic. This result may also indi-
cate evidence of subjective symptoms of patients, such
as “weakness, getting tired quickly and desire to sleep
for a long time”. However, when patients are assessed in
accordance with the results obtained from the HBQOL
questionnaire, patients feel well via spiritual means and
have an intense desire to live. Nevertheless, even though
patients were considered to be in a positive mental con-
dition, they were somehow anxious about matters in the
future, and furthermore the majority of patients did not
have stigmata or vulnerability emotions. When these
data were assessed together, we determined that the
anxious status of CHB patients was not related to the
community, but highly focused on medical issues. In
the present study, we can admit that the HRQOL of
Table 6 Covariance analysis of factors associated with Hepatitis
B Quality of Life total score among all study participants
Variables included in the Model Mean square F Sig.
Gender 8186,916 26,001 <0,001
Marriage status 6385,542 20,280 <0,001
Other chronic disease 4789,179 15,210 <0,001
HBeAg status 480,405 1526 0,217
ALT level 2547,493 8091 0,004
Hospital type 716,785 2276 0,131
Received treatment for hepatitis B 1020,020 3240 0,072
Inactive disease 3017,300 9583 0,002
R2 = 0,048 (Adjusted R2 = 0,046), Dependent Variable: total scores,
ALT Alanine aminotransferase
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patients that participated in the study related to CHB
was considerably better when a total median score of >80
were considered.
Our study is one of the largest studies conducted in
Turkey where HRQOL scores have been studied in CHB
patients who are carefully monitored, and can be consid-
ered valuable due to the data obtained from patients
who resided in different geographical regions and who
were monitored in different types of hospitals. Even
though its validity was previously tested in a Turkish
population, there have been no studies published where
a HBQOL scale was utilized.
Showing attention to some limitations of our study re-
garding the planning process could be helpful for future
studies. Nevertheless, the results obtained from this
study may not be generalizable to all CHB patients in
Turkey. As the HBQOL was not developed for the
population of cirrhotic patients, this group of patients
was not included in the study. As the subscale of trans-
missibility is not appropriate to be used in the Turkish
population, we do not recommend using the current
HBQOL scale developed as is. Another limitation en-
countered in our study was that it may be impossible to
determine the status effect ability related to the type of
therapy since the HRQOL was not planned to be used
as an assessment according to the type of therapy. The
cross-sectional qualification and design of the current
study, progression of the disease in patients and variance
in the quality of life among patients during the monitoring
period has limited the collection of data.
Conclusions
The quality of life of CHB patients in the study group
was found to be relatively high when assessed with the
values obtained by the SF-36 and HBQOL scales. The
quality of life is dependent on factors related to a number
of individual factors and the course of the disease.
The quality of life can become negatively affected
once the activity of the disease is increased. However,
appropriate antiviral therapy can provide a higher quality
of life in this group of patients. Proper assessment and
management of CHB along with psychiatric support for
female or single patients with active disease and comor-
bidities should be taken into consideration.
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